Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study

2016 ◽  
Vol 46 (6) ◽  
pp. 555-563 ◽  
Author(s):  
Christian L. Hvas ◽  
Anders Dige ◽  
Mia Bendix ◽  
Pernille G. Wernlund ◽  
Lisbet A. Christensen ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Pilot Study ◽  
Distal Ulcerative Colitis

scholarly journals Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis — A randomized, placebo-controlled, pilot study

2014 ◽  
Vol 8 (3) ◽  
pp. 208-214 ◽  
Author(s):  
Vikas Singla ◽  
Venigalla Pratap Mouli ◽  
Sushil Kumar Garg ◽  
Tarun Rai ◽  
Bikash Narayan Choudhury ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Pilot Study ◽  
Distal Ulcerative Colitis

MON-PP058: Randomised Clinical Trial: Casein Glycomacropeptide for Active Distal Ulcerative Colitis – A Pilot Study

2015 ◽  
Vol 34 ◽  
pp. S149 ◽  
Author(s):  
P.G. Wernlund ◽  
C.L. Hvas ◽  
L.A. Christensen ◽  
J.F. Dahlerup ◽  
M.B. Rasch ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Pilot Study ◽  
Randomised Clinical Trial ◽  
Distal Ulcerative Colitis

Efficacy of mesalamine rectal gel in distal ulcerative colitis. A pilot study

2003 ◽  
Vol 124 (4) ◽  
pp. A379
Author(s):  
Guy Aumais ◽  
Marc Lefebvre ◽  
Julie Massicotte ◽  
Claude Tremblay ◽  
Katcha Pierre ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Pilot Study ◽  
Distal Ulcerative Colitis

EVALUATION OF A DIET AND ANTIBIOTICS TARGETING THE MICROBIOTA FOR TREATMENT OF MILD TO MODETARE ACTIVE PEDIARTIC ULCERATIVE COLITIS: AN OPEN LABEL PILOT STUDY

2021 ◽  
Vol 27 (Supplement_1) ◽  
pp. S38-S38
Author(s):  
Chen Sarbagili-Shabat ◽  
Lindsey Albenberg ◽  
Johan Van Limbergen ◽  
Dror Weiner ◽  
Michal Yaakov ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Pilot Study ◽  
Dietary Intervention ◽  
Activity Index ◽  
Fecal Calprotectin ◽  
Dietary Therapy ◽  
The Novel ◽  
Open Label ◽  
Intention To Treat ◽  
Stable Maintenance

Abstract Background Newer strategies that target the microbiome may offer an alternative therapeutic approach for Ulcerative Colitis (UC). We developed a novel diet that targets changes in the microbiome and barrier function that have been reported in UC. The goal of the current study was to evaluate the efficacy of two sequential induction of remission strategies that target the microbiota: the novel diet termed the ulcerative colitis diet (UCD) and an antibiotics cocktail combination in dietary non responders. Methods This was a prospective, single arm, open label, pilot study in patients aged 8–19, with a pediatric UC activity index (PUCAI) scores >10 and ≤45 on stable maintenance therapy (5ASA or thiopurines). PUCAI score was assessed at week 3 and 6. Patients failing to enter remission or intolerant to dietary therapy could receive an open label 14-day course of Amoxycillin, Metronidazole and Doxycycline (AMD), and had PUCAI scored at day 21. Response was defined a decline in PUCAI ≥ 10 points, remission as PUCAI< 10. The primary endpoint was intention to treat (ITT) remission at week 6 with diet as the sole intervention. Results Twenty-three children mean age of 15.1±2.9 years were enrolled. Two patients (1 responder, 1 remission) withdrew by 3 weeks, four required additional therapy by week 3, all were considered failures by ITT. Mean PUCAI decreased at week 3 and 6 from 34.5±9.8 to 21.7±14.9 and 17.6±17.2 respectively (P=0.005, P=0.001) at ITT analysis including all patients. Sixteen out of twenty-three patients (69.6%) responded by week 6. Ten of twenty-three (43.5%) achieved remission by week 6, and nine (39.1%) had clinical remission at week 6. The median fecal calprotectin (FC) level decreased in patients (n=5) who achieved remission from 630 (IQR, 332–1586) μg/g at week 0 to 230 (75–1298) μg/g at week 6. Eight patients received treatment with antibiotics after failing diet, 4/8 (50.0%) subsequently entered remission. Conclusion A dietary intervention called the UC Diet appears to be effective for induction of remission in children with mild to moderate UC. Sequential use of diet, followed by antibiotic therapy in dietary non responders, needs further evaluation as a microbiome directed steroid sparing therapy in patient’s refractory to 5ASA and thiopurines.

scholarly journals Creatine Supplementation for Patients with Inflammatory Bowl Diseases: A Scientific Rationale for a Clinical Trial

Nutrients ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1429
Author(s):  
Theo Wallimann ◽  
Caroline H. T. Hall ◽  
Sean P. Colgan ◽  
Louise E. Glover
Keyword(s):  
Ulcerative Colitis ◽  
Clinical Trial ◽  
Crohn’S Disease ◽  
Pilot Study ◽  
Crohn's Disease ◽  
Single Case ◽  
Initial Period ◽  
Creatine Supplementation

Based on theoretical considerations, experimental data with cells in vitro, animal studies in vivo, as well as a single case pilot study with one colitis patient, a consolidated hypothesis can be put forward, stating that “oral supplementation with creatine monohydrate (Cr), a pleiotropic cellular energy precursor, is likely to be effective in inducing a favorable response and/or remission in patients with inflammatory bowel diseases (IBD), like ulcerative colitis and/or Crohn’s disease”. A current pilot clinical trial that incorporates the use of oral Cr at a dose of 2 × 7 g per day, over an initial period of 2 months in conjunction with ongoing therapies (NCT02463305) will be informative for the proposed larger, more long-term Cr supplementation study of 2 × 3–5 g of Cr per day for a time of 3–6 months. This strategy should be insightful to the potential for Cr in reducing or alleviating the symptoms of IBD. Supplementation with chemically pure Cr, a natural nutritional supplement, is well tolerated not only by healthy subjects, but also by patients with diverse neuromuscular diseases. If the outcome of such a clinical pilot study with Cr as monotherapy or in conjunction with metformin were positive, oral Cr supplementation could then be used in the future as potentially useful adjuvant therapeutic intervention for patients with IBD, preferably together with standard medication used for treating patients with chronic ulcerative colitis and/or Crohn’s disease.

scholarly journals Treatment of distal ulcerative colitis (proctosigmoiditis) in relapse: comparison of hydrocortisone enemas and rectal hydrocortisone foam.

Gut ◽  
1980 ◽  
Vol 21 (10) ◽  
pp. 885-889 ◽  
Author(s):  
W S Ruddell ◽  
R J Dickinson ◽  
M F Dixon ◽  
A T Axon
Keyword(s):  
Ulcerative Colitis ◽  
Distal Ulcerative Colitis

Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: A multicenter, randomized, double-blind study

2007 ◽  
Vol 39 (4) ◽  
pp. 329-337 ◽  
Author(s):  
L. Biancone ◽  
P. Gionchetti ◽  
G. Del Vecchio Blanco ◽  
A. Orlando ◽  
V. Annese ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Beclomethasone Dipropionate ◽  
Blind Study ◽  
Double Blind Study ◽  
Double Blind ◽  
Distal Ulcerative Colitis
Sign in / Sign up

Export Citation Format

Share Document